Purchase this article with an account.
Y. Benayoun, J.-P. Adenis, G. Casse, P.-Y. Robert; Effects of Subconjunctival Bevacizumab on Corneal Neovascularization : Results of a Prospective Study. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5700.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
This work aimed to study and evaluate the effect of subconjunctival bevacizumab injection in patients with corneal neovascularization resulting from different ocular surface disorders.
The study is a prospective case series that includes 12 eyes of 11 patients with corneal neovascularization caused by different ocular surface disorders such as healed corneal ulcers, long-standing chronic inflammatory diseases and corneal ischaemia secondary to burn. All eyes received a single subconjunctival injection of 2.5 mg (0.1 ml) bevacizumab. Morphological changes in vessels were evaluated using slit-lamp biomicroscopy , corneal digital photography and computed-assisted semi-automatic analysis of corneal neovascularization area.
Recession of corneal vessels was observed in all eyes at 1 weeks post-injection. The area of corneal neovascularization continued to decrease noticeably for 1 month and then stabilized or increased again for the remainder of the 3 month follow-up period. The total area of corneal neovascularization, which amounted to 14.2 % +/- 5.2 % of the corneal surface pre-injection, compared with 10.8 % +/- 3.8 % post-injection (p < 0.001), reflecting a mean decrease in corneal neovascularization of 24.1 %. During the 3 month follow-up, none of the 11 patients showed any local or systemic adverse events that could be related to subconjunctival bevacizumab injection.
Short-term results suggest that bevacizumab can be used safely and effectively for corneal neovascularisation resulting from different ocular surface disorders. It may provide an additional strategy in improving vision or improving success of corneal grafts in these patients.
This PDF is available to Subscribers Only